PCSK9 and atherosclerosis - lipids and beyond

Michael D. Shapiro, Sergio Fazio

    Research output: Contribution to journalReview articlepeer-review

    62 Scopus citations


    Even though it is only a little over a decade from the discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) as a plasma protein that associates with both high and low cholesterol syndromes, a rich body of knowledge has developed, and drugs inhibiting this target have been approved in many markets. While the majority of research in recent years has focused on the impact of therapeutic antagonism of this molecule, important lines of investigation have emerged characterizing its unique physiology as it relates to cholesterol metabolism and atherosclerosis. The PCSK9 story is unfolding rapidly but is far from complete. One chapter that is of particular interest is the possible direct link between PCSK9 and atherosclerosis. This review specifically examines this relationship drawing from data produced from experimental models of plaque biology and inflammation, atherosclerosis imaging studies, and observational epidemiology.

    Original languageEnglish (US)
    Pages (from-to)462-472
    Number of pages11
    JournalJournal of Atherosclerosis and Thrombosis
    Issue number5
    StatePublished - 2017


    • Atherosclerosis
    • Hypercholesterolemia
    • Inflammation
    • Lipid metabolism
    • Low density lipoprotein
    • Proprotein convertase subtilisin/kexin type 9

    ASJC Scopus subject areas

    • Internal Medicine
    • Cardiology and Cardiovascular Medicine
    • Biochemistry, medical


    Dive into the research topics of 'PCSK9 and atherosclerosis - lipids and beyond'. Together they form a unique fingerprint.

    Cite this